Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Cash (2020 - 2025)

Historic Change in Cash for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$5.8 million.

  • Insight Molecular Diagnostics' Change in Cash rose 196.84% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 24536.47%. This contributed to the annual value of -$796000.0 for FY2024, which is 9340.57% up from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Change in Cash is -$5.8 million, which was up 196.84% from -$6.7 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Change in Cash ranged from a high of $51.8 million in Q1 2021 and a low of -$15.2 million during Q1 2022
  • In the last 5 years, Insight Molecular Diagnostics' Change in Cash had a median value of -$4.4 million in 2023 and averaged $598263.2.
  • Over the last 5 years, Insight Molecular Diagnostics' Change in Cash had its largest YoY gain of 104184.86% in 2021, and its largest YoY loss of 577945.21% in 2021.
  • Over the past 5 years, Insight Molecular Diagnostics' Change in Cash (Quarter) stood at -$7.7 million in 2021, then plummeted by 36.39% to -$10.5 million in 2022, then skyrocketed by 58.76% to -$4.4 million in 2023, then surged by 221.19% to $5.3 million in 2024, then plummeted by 209.56% to -$5.8 million in 2025.
  • Its last three reported values are -$5.8 million in Q3 2025, -$6.7 million for Q2 2025, and $22.4 million during Q1 2025.